2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness
美国传染病学会2025年COVID-19治疗和管理临床实践指南更新:Pemivibart用于暴露前预防,Vilobelimab用于危重症,Abatacept或Infliximab用于重症或危重症。
期刊:Clinical Infectious Diseases
影响因子:7.3
doi:10.1093/cid/ciaf424
Bhimraj, Adarsh; Falck-Ytter, Yngve; Baden, Lindsey R; Bedimo, Roger; Cawcutt, Kelly; Cheng, Vincent Chi-Chung; Chew, Kara W; Chiotos, Kathleen; Daar, Eric S; Dzierba, Amy L; Glidden, David V; Hardy, Erica J; Johnson, Steven; Kim, Arthur Y; Li, Jonathan Z; MacBrayne, Christine; Martin, Greg S; Nadig, Nandita; Nakamura, Mari M; Pearson, Jeffrey C; Riley, Laura; Shafer, Robert W; Shoham, Shmuel; Shumaker, Amy Hirsch; Tebas, Pablo; Tien, Phyllis C; Loveless, Jennifer; Morgan, Rebecca L; Gandhi, Rajesh T